Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874331 | 0.82 | DGAT1 (0.38) | DGAT1TDP1MEN1KMT2A | |
| SCHEMBL22874322 | 0.82 | DGAT1 (0.38) | DGAT1TDP1MEN1KMT2A | |
| SCHEMBL2280101 | 0.79 | DGAT1 (0.42) | DGAT1TDP1CA14CA1CA7 | |
| SCHEMBL2276383 | 0.76 | DGAT1 (0.39) | DGAT1TDP1CA14CA12CA2 | |
| SCHEMBL22874323 | 0.75 | TSHR (0.34) | TDP1MEN1KMT2A | |
| SCHEMBL22874327 | 0.75 | TSHR (0.34) | TDP1MEN1KMT2A | |
| SCHEMBL16976213 | 0.72 | DGAT1 (0.52) | DGAT1TDP1CA1CA7CA2 | |
| SCHEMBL20980675 | 0.72 | — | — | |
| SCHEMBL14947771 | 0.72 | — | — | |
| SCHEMBL20369817 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989649-B2 | Tumor imaging compounds | EMORY UNIVERSITY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1499584-B1 | TUMOR IMAGING COMPOUNDS | UNIV EMORY (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2009-09-24 | — | — | US | disclosed |
| CN-101041674-A | Tumor imaging compounds | UNIV EMORY (US) | 2007-09-26 | — | — | CN | disclosed |
| EP-1499584-A4 | TUMOR IMAGING COMPOUNDS | UNIV EMORY (US) | 2007-08-15 | — | — | EP | disclosed |
| CN-1313436-C | Tumor imaging compounds | UNIV EMORY (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1649828-A | Tumor imaging compounds | UNIV EMORY (US) | 2005-08-03 | — | — | CN | disclosed |
| EP-1499584-A2 | TUMOR IMAGING COMPOUNDS | Emory University (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093412-A2 | TUMOR IMAGING COMPOUNDS | EMORY UNIVERSITY (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240041-A1 | TUMOR IMAGING COMPOUNDS | AADAT, MKI67, SSTR1 | DGAT1 4582/4885TDP1 4506/4885CA14 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.